Category Archives: Health

Clinical Studies Highlight the Potential of Tesla BioHealing Biophoton Generator in Improving Mobility for Chronic Stroke Patients

Butler, PA, July 26, 2024 — First Institutes of All Medicines conducted randomized, double-blind and placebo-controlled clinical study to determine effectiveness of the Tesla BioHealing Biophoton Generator when used by 42 chronic stroke patients.

The newly completed clinical studies indicate that the Tesla BioHealing® Biophoton Generator may help enhance mobility in patients with chronic stroke conditions. These outcomes represent a significant step forward in addressing permanent disability caused by strokes. Initial small-scale studies provided sufficient evidence to justify a larger confirmatory clinical study.

Led by Dr. Mariola Smotrys at the First Institute of All Medicines, a randomized, double-blind and placebo-controlled clinical study was conducted in 42 patients with chronic stroke. The majority of patients treated with the Tesla BioHealing® Biophoton Generator experienced improvements in mobility and quality of life. The results suggest that this technology could provide new hope for many stroke survivors.

Dr. Lawrence Alpert, the study physician, shared his positive perspective on the findings. “The Tesla BioHealing® Biophoton Generator, currently available as a wellness product, has shown promise in stroke rehabilitation,” said Alpert. “Clinical trials have demonstrated that this device can significantly improve the quality of life for chronic stroke patients, offering them a chance to regain independence and mobility.”

The Tesla BioHealing® Biophoton Generator emits ultra-high biophotons that support cellular repair, regeneration and communication. This non-invasive treatment works with the body’s natural healing processes, providing a safe and potentially effective solution for stroke patients who have not benefited from conventional rehabilitation methods after six months.

“I experienced significant improvements after using the Tesla Biophoton Generator,” said Les Duncan, a 74-year-old six-time stroke survivor. “My pain and brain fog have cleared, and I no longer need a walker. I feel like a new person.”

Dr. James Liu, CEO of Tesla BioHealing, Inc. stated that the new results of the clinical studies encourage our organization to develop a safe, effective and easy to use product to benefit patients. We are to prepare and apply regulatory approval. Our goal is to advance this innovative technology to benefit millions of patients with chronic stroke.

Forward-Looking Statements

This press release contains forward-looking statements that involve certain risks and uncertainties. These statements include, but are not limited to, potential benefits of Tesla BioHealing® products. Factors that could cause actual results to differ materially include risks that clinical development activities may be delayed or unsuccessful, that products may not be approved or commercially viable and that regulatory decisions may be unfavorable. Tesla BioHealing Inc. and the First Institute of All Medicines (FIAM) disclaim any obligation to update these statements after the date hereof except as required by law.

Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience

July 25, 2024,New York, United States : Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience.

“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Ph.D. chief clinical science & operations officer, at Eisai. “Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”

Clinical Data Studio is powered by the Medidata Platform, the industry’s only unified platform that centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem. By seamlessly integrating data from both Medidata sources, including Medidata Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system, Clinical Data Studio streamlines the import process and enables automatic validation through configured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate data systems and offers up to 80 percent faster data review while providing a comprehensive view of patient data that can be concurrently reviewed, visualized, and acted on.

“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data,” said Janet Butler, executive vice president, global head of sales, Medidata. “By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.”

BD India’s Concerted Commitment Towards Creating Awareness About Venous Diseases

24th July 2024  New Delhi, Delhi, India  To create awareness and enable knowledge-sharing around Venous diseases, in order to drive better patient care BD (Becton, Dickinson, and Company) conducted roadshows across New Delhi, Mumbai and Bangalore recently. Venous disease is a condition where the veins in the body have difficulty returning blood to the heart, thereby resulting in blood clot forming in a vein, typically in the legs. If left untreated, these clots can break loose and travel to the lungs, causing serious complications. Delayed detection and intervention can lead to worsened clinical outcomes and a multitude of problems for both patients and healthcare professionals.

The 3-day Venous Summit witnessed a series of Technology Innovation Forums followed by Symposiums driven by Dr. Houman Jalaie, Head of Venous Commission of German Society of Vascular Surgery and Deputy Head of Department of Vascular & Endovascular Surgery, University Hospital Aachen, Germany and over 40 prominent faculty from Interventional Radiology, Vascular Surgery from ~12 cities across India. Attended by 200+ delegates with 13 case-presenters who drove 8.5 hours of scientific discussions each day, the end objective of the Summit was to discuss best domestic and international practices in order to drive better patient care in the venous domain in India.

Commenting on this initiative to establish Standard of care for Venous disease patients in India, Atul Grover, Managing Director, India, South Asia, “Venous Diseases are slow progressive diseases which exist very commonly but often go untreated owing to low levels of awareness and lack of diagnosis. Through our Venous Summit, in partnership with experts like Dr. Houman Jalaie we are bringing the focus on Venous ailments as well as providing a platform to healthcare experts from across the country to establish a uniform quality care protocol to enable better patient care. This initiative is aligned with BD’s purpose of advancing the world of health by delivering superior patient outcomes.”

Dr. Houman Jalaie shared his knowledge with healthcare professionals through a series of events which touched upon the following areas:

• Uniform treatment algorithms in Post-Thrombotic Syndrome and NIVL management
• Approaches to learn and adapt from current International and National best practices in Deep Vein Thrombosis (DVT) Management
• How novel technologies, like mechanical thrombectomy, can improve the patient outcomes in complex venous diseases

Reflecting on his experience, Dr. Jalaie said, “As a healthcare professional, there is nothing more important for me than the safety and wellbeing of my patients. I was delighted to interact with so many like-minded senior doctors from all over India to discuss the right strategies to enable better patient outcomes.”

Every year over 2 million patients in India suffer from some form of Venous disease, however, due to less awareness, many patients go undiagnosed or untreated.

Demystifying Varicose Veins: Sri Ramakrishna Hospital’s Vascular Specialists Illuminate the Path to Effective Management

22nd July 2024  Coimbatore, Tamil Nadu, India  Dispelling misconceptions surrounding varicose veins, experts at Sri Ramakrishna Hospital delve into the condition’s nuances, offering insights into symptoms, symptom management, and prevention strategies.

Varicose veins, predominantly affecting the lower limbs, stem from weakened or damaged veins, disrupting blood flow to the heart. Contrary to common belief, they extend beyond cosmetic concerns, potentially leading to discomfort and health complications.

Identifying Symptoms:

• Visible, enlarged veins in the legs
• Leg throbbing or cramping
• Leg pain or achiness
• Sensation of leg heaviness
• Leg swelling
• Skin color changes around affected veins

Effective Management Tips:

• Engage in regular circulation – promoting exercises like walking or swimming.
• Elevate legs above heart level during rest to alleviate swelling and enhance circulation.
• Utilize compression stockings to enhance blood flow and alleviate symptoms.
• Maintain a balanced, nutrient-rich diet to support vascular health.
• Avoid prolonged periods of sitting or standing to prevent blood pooling in the legs.

Preventive Measures:

• Maintain a healthy weight to reduce pressure on veins.
• Avoid tight clothing that impedes blood flow, particularly around the waist and legs.
• Stay hydrated to support circulation and vein health.
• Quit smoking to mitigate vascular issues.
• Schedule regular checkups with vascular specialists for proactive monitoring and timely intervention.

Dispelling Myths:

1. Myth: Varicose veins are untreatable.
Fact: Medical advancements offer effective treatments, rendering this myth obsolete.

2. Myth: Varicose veins are solely cosmetic concerns.
Fact: Beyond aesthetics, varicose veins can impact overall health, emphasizing the need for prompt treatment.

3. Myth: Varicose veins exclusively affect women.
Fact: While common in women, men are also susceptible to varicose veins.

4. Myth: Varicose veins only afflict the elderly.
Fact: Varicose veins can develop at any age due to various factors, not just aging.

While often asymptomatic, varicose veins warrant attention and care. Sri Ramakrishna Hospital offers advanced, outpatient treatments, ensuring comfort and accessibility for individuals seeking relief from symptoms and complications associated with varicose veins.

Carlton Senior Living San Leandro Achieves Teepa Snow Positive Approach to Care Designation

San Leandro, CA, July 20, 2024 — This prestigious designation is part of a broader achievement across multiple Carlton communities, including Downtown Pleasant Hill, Davis, Orangevale, Sacramento, and San Jose. It joins already PAC-designated Carlton communities in Elk Grove and Fremont. Remarkably, eight of the ten PAC-designated organizations in the Western United States are Carlton communities, making them the sole PAC-designated senior living provider in Northern California.

At the heart of this accomplishment are the philosophy and teachings of Teepa Snow, a renowned occupational therapist and dementia care educator. Her Positive Approach to Care® has revolutionized the way we understand and support individuals living with dementia. Snow’s methods are recognized globally and recently garnered attention for her advisory role in supporting actor Bruce Willis and his family in navigating his care after his diagnosis of frontotemporal dementia.

Understanding PAC
PAC is a holistic philosophy emphasizing empathy, dignity, and respect in all interactions with individuals with dementia. This approach recognizes each person’s unique life history, abilities, and preferences, guiding their journey with person-centered care.

Key Elements of PAC include:

· Person-centered care involves customizing care plans and interactions to meet the individual’s needs, preferences, and abilities.

· The Gems® Model helps care partners understand the stages of dementia, enabling them to adjust their approach accordingly.

· Positive communication, using clear, simple language, maintaining eye contact, and fostering a supportive environment are essential.

· Skill building equips care partners with practical skills to empower seniors, promote independence, and enhance quality of life.

Benefits of PAC for Individuals Living with Dementia and Their Families

PAC offers numerous benefits to individuals living with dementia and their families.

· Individuals maintain autonomy and experience a higher quality of life by focusing on individual strengths and preferences.

· Care partners gain confidence and competence through PAC® education and training. Positive communication techniques foster deeper connections between individuals, care partners, and families.

· PAC® reduces stress and frustration by promoting understanding, empathy, and effective coping strategies.

Evelyn Jensen, Executive Director of Carlton Senior Living San Leandro, shared her enthusiasm about this achievement, stating, “I am so proud of our team for embracing Teepa Snow’s Positive Approach to Care®. This designation highlights our continuous effort to provide compassionate and innovative dementia care, aligning perfectly with Carlton’s three commitments: Love, Honor, and Provide.”

Jensen, who has extensive experience working with individuals living with dementia as the past executive director of Memory Care of Contra Costa, added, “I have witnessed firsthand the transformative power of Positive Approach to Care® and how it has connected residents, staff, and families.”

In achieving the Positive Approach to Care® designation, Carlton Senior Living reaffirms its dedication to excellence, compassion, and innovation in dementia care.

Yashoda Super Speciality Hospitals: A Legacy of Excellence in Medical Care and Commitment

20th July 2024  Ghaziabad, Uttar Pradesh, India  Established 15 years ago, Yashoda Super Speciality Hospitals Kaushambi has emerged as a beacon of excellence in healthcare across North India. From its inception, the hospital has been dedicated to providing affordable yet world-class healthcare services adhering to the highest standards of medical ethics and compassion.

Yashoda Super Speciality Hospitals accommodates healthcare professionals across a spectrum of medical disciplines providing exceptional medical and clinical services along with high-quality education and training opportunities. Over the years, they have solidified their position as a leading institution in India’s healthcare sector, distinguished for their expertise in specialized treatments, intricate surgeries, international standards, and advanced infrastructure. Yashoda’s commitment extends to serving communities with outstanding patient care marked by compassionate dedication and significant efforts.

The hospital’s ethos revolves around care and concern for patients and their families, commitment to continuous learning, teamwork, integrity in all internal operations, and pursuit of excellence through skilful execution. This philosophy not only guides the hospital’s daily operations but also inspires its medical professionals to excel in their fields.

Yashoda Super Speciality Hospitals boasts state-of-the-art infrastructure equipped with the latest technological advancements. This includes advanced diagnostic facilities, modern surgical theatres, and specialized treatment units for complex surgeries and super-specialty treatments. The hospital’s dedication to staying at the forefront of medical innovation has earned it accolades and recognitions, including being ranked 1st in the Times Health Survey’s All India Critical Care Hospital Ranking Survey for the NOIDA and Ghaziabad Zone in 2022, and 12th in the Multi-specialty Hospitals category for the Northern Region Zone.

In addition to its clinical excellence, Yashoda Super Speciality Hospitals is renowned for its compassionate approach to patient care. Every member of the hospital’s staff is committed to ensuring that each patient receives personalized attention and the highest quality of medical treatment.

Under chairman, Dr. P N Arora’s visionary leadership, Yashoda Super Speciality Hospitals has grown to become a comprehensive healthcare system offering multispecialty tertiary care services. Dr. Arora’s commitment to quality patient care and innovative healthcare solutions has been instrumental in shaping the hospital’s journey toward excellence.

“Yashoda Super Speciality Hospitals is committed to integrating cutting-edge technology with compassionate patient care. Our mission is to deliver world-class healthcare services with a focus on quality, service excellence, empathy, and world-class healthcare services. Our vision is to create a comprehensive and integrated healthcare facility that not only treats illnesses but also promotes overall well-being. We aim to continue expanding our capabilities and services to meet the evolving healthcare needs of our community,” adds Dr. P N Arora.

Over the years, some of the prestigious awards and accolades Yashoda Super Speciality Hospitals has garnered include the AHPI Healthcare Excellence Award for “Best Hospital to Work For” and the 1st prize in Swachh Survekshan 2022 in the Ghaziabad zone. These accolades are a testament to the hospital’s commitment to excellence in healthcare delivery and patient satisfaction.

Yashoda Super Speciality Hospital reaffirms its dedication to providing accessible, affordable, and top-notch healthcare services to the people of India. With a solid foundation built on integrity, compassion, and innovation the hospital looks forward to continuing its journey as a leader in the healthcare industry, setting new benchmarks for excellence and patient care. These efforts collectively contribute to establishing Yashoda Super Speciality Hospitals as a premier healthcare provider in the Delhi NCR region.

MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy

Newton, MA, July 17, 2024 — Courage, a pre-clinical stage biotech company, announced groundbreaking results, funded in part by an NIDDK funded STTR research grant on obesity. The article “Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice” was published in the Journal of Clinical Investigation by senior author and Courage co-founder Dr. Roger Cone. It reports on synergy between GLP1RA and MC4R agonist drugs, demonstrating that low doses of MC4R agonists can significantly improve the dose-responsiveness of GLP1RA drugs to reduce food intake and drive weight loss through a novel mechanism that can improve GLP1RA weight loss efficacy without increasing side effects.

“This synergy between the MC4R circuit and GLP1RA agents could revolutionize the obesity treatment landscape similar to how GLP1/GIP combinations such as tirzepatide have recently shown dramatic improvements in weight loss,” said Dan Housman CEO.

Courage completed a successful four-year drug discovery campaign resulting in a market leading portfolio of optimized MC4R peptide agonist drug candidates designed to address the combination opportunity. Clinical candidates have demonstrated significantly higher potency and selectivity in animal models than setmelanotide, the only MC4R agonist currently approved for obesity treatment. The selectivity eliminates MC1R activity which drives a pigmentation side effect that has limited pharma development of MC4R agonists in dietary obesity. Combining Courage products with GLP1RA drugs such as Ozempic and Mounjaro in new ways is expected to improve the safety of GLP1RA drugs by lowering nausea, increasing physical activity, and reducing gastrointestinal discomfort.

“Based on their deep expertise in the field of melanocortin biology, Courage scientists have developed a range of peptide drugs that activate the MC4R. The potency and specificity of these drugs represent a significant advance on the only currently licensed activator of this receptor, setmelanotide. Their current paper in the Journal of Clinical Investigation Dahir et al adds to the evidence that combining low doses of a melanocortin 4 agonist with anti-obesity drugs acting through the GLP1Receptor can lead to greater weight loss in mice than when these drugs are used alone. Combining a specific and potent MC4R agonist with a drug acting on GLP1R opens up the exciting possibility of novel “dual action” anti-obesity agents with improved efficacy, safety and tolerability said Stephen O’Rahilly, Professor of Clinical Biochemistry and Medicine at the University of Cambridge and chair of Courage’s Scientific Advisory Board.

The company is initiating pre-clinical studies to bring product candidates into the clinic. Additionally, Courage is seeking partnerships with GLP1RA drug companies.
Go to the article: “Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice,” Journal of Clinical Investigation.

How New Research Could Change the Way We Fight the Opioid Epidemic

Jupiter, FL, July 17, 2024 — New research from a Max Planck Florida Institute for Neuroscience researcher could transform how we understand the way opioids affect the brain. Despite significant discussion surrounding the ongoing opioid crisis, current understanding of how opioids function in the brain is quite limited. This is primarily due to challenges in observing and measuring opioid effects in the brain in real-time. However, a recent technological breakthrough, led by Dr. Lin Tian and her research team and collaborators, recently published in Nature Neuroscience, has overcome these limitations and is set to transform how scientists study opioid signaling in the brain.

What do we know about opioid signaling?

Pharmaceutical opioids, such as morphine and oxycodone, and illicit opioid drugs like heroin, affect the brain and body by binding to opioid receptors on the surface of cells in the nervous system. These receptors normally respond to naturally produced chemicals that are released in your brain, called endogenous opioids, including endorphins, enkephalins, and dynorphins.

Released in response to pleasurable activities such as laughter, sex, and exercise and aversive activities like injury and trauma, these chemicals bind opioid receptors and reduce the ability of neurons to receive and transmit signals. These cellular effects ultimately lead to the cognitive and behavioral effects associated with opioids, including positive feelings, pain relief, and addiction.

Challenges in understanding opioid signaling
Numerous questions remain about how these behavioral effects are caused by opioids and whether it is possible to harness specific opioid properties such as pain relief without undesirable effects, such as addiction. The opioid scientific literature is extensive and has confirmed that targeting the opioid system is of clinical interest – not only for pain management but also, more recently, for the treatment of mental health disorders such as anxiety and depression. Development of therapeutics that can target these health challenges while preventing the tragedy of the current opioid epidemic requires further understanding of the diverse effects of opioids in the brain.

The diversity of opioid effects on the brain is driven by more than 20 different opioid chemicals produced in the brain and more than 500 different synthetic opioids. Most of these different opioids interact with all three types of opioid receptors with different strengths. Their varied effects depend on the concentration of opioid, the specific receptors present and the brain circuits involved.

“Efforts are underway to harness various therapeutic properties of opioids by targeting specific receptor actions and brain circuits to develop more effective and safer therapeutics. However, these efforts have been hampered by our inability to measure diverse opioid signaling in real time in the brain effectively,” said Dr. Tian.
New technology opens door to understanding opioids in brain
Through a massive effort developing and testing over 1,000 variants, Dr. Tian’s team has optimized highly-sensitive biosensors based on the three opioid receptors. These biosensors, originally developed while Tian was at the University of California, Davis, emit fluorescence upon opioid binding to the sensor and turn off when the opioid is no longer there. The biosensors, therefore, serve as a proxy for opioid binding to specific opioid receptors.

Introducing these sensors into the brain of an animal provides a way to visualize opioid signaling across the brain in real-time.

“The power of this new technology is that we now have the tools to understand the natural opioid system in the brain, including how to distinguish between different opioid effects. We can track endogenous opioid release in real-time, triggered by both reward and aversion and see the differences in opioid signaling in different brain circuits.”

Dr. Tian’s team has already been sharing these new tools widely to accelerate the impact this new technology will have on the understanding of opioids.

Citation:
Title: Unlocking opioid neuropeptide dynamics with genetically-encoded biosensors Authors: Chunyang Dong, Raajaram Gowrishankar, Yihan Jin, Xinyi Jenny He, Achla Gupta, Huikun Wang, Nilüfer Sayar Atasoy, Rodolfo Flores-Garcia, Karan Mahe, Nikki Tjahjono, Ruqiang Liang, Aaron Marley, Grace Or Mizuno, Darren Kirin Lo, Qingtao Sun, Jennifer L. Whistler1, Bo Li, Ivone Gomes, Mark Von Zastrow, Hugo A Tejeda, Deniz Atasoy, Lakshmi A Devi, Michael R. Bruchas, Matthew R. Banghart, Lin Tian
Journal: Nature Neuroscience

BD Launches the TB Guardianship Program

16th July 2024 New Delhi, Delhi, India  To further enhance knowledge exchange amongst healthcare professionals on effective TB diagnostic practices, BD (Becton, Dickinson, and Company), a Corporate TB Pledge holder has recently launched the ‘TB Guardianship Program’. The TB Guardianship Program was launched online by esteemed dignitary Dr. Nishant Kumar, Central TB Division under the Ministry of Health and Family Welfare and saw attendance from over 1,000 microbiologists and pulmonologists from various regions across India.

A tri-partite educational series; in collaboration with several esteemed partners, including the Indian Chest Society (ICS), the Central TB Division (CTD), the International Union Against Tuberculosis and Lung Disease (The Union), Corporate TB Pledge and USAID, the program aims to improve TB diagnosis and Drug Susceptibility testing.

Commenting on the launch and the initiative, Atul Grover, Managing Director, BD India/South Asia said, “BD is a Corporate TB Pledge Holder and has been at the forefront of fostering knowledge exchange and collaboration in the fight towards TB elimination. We are committed to advancing the world of health through our TB Guardianship Program – an initiative geared to enhance effective TB diagnostic practices amongst healthcare professionals.”

The TB Guardianship Program, through this 3 part webinar series will provide a platform for discussion and debate on key topics like – Understanding the Dynamic landscape of diagnosing and managing Drug-Resistant Tuberculosis (DR-TB); Emphasizing the pivotal role of liquid culture and the efficacious management of tuberculosis (TB) and multidrug-resistant TB (MDR-TB) pivots on the expeditious diagnosis & precision in treating resistant infections amongst others.

Dr Rakesh PS, Public Health Intervention Specialist at the International Union Against Tuberculosis and Lung Disease said, “Our aim is to raise public awareness about the devastating health, social and economic consequences of TB, and to step up efforts to end the global TB epidemic. We are confident that the TB Guardianship Program will foster the best practices among health care professionals.”

After each series, participants will receive certificates as a token of their active participation. Additionally, exciting on-ground activities are planned at select Revised National Tuberculosis Control Program (RNCTP) sites.

BD has a long history in TB diagnostics, having launched the first automated liquid culture system, the BD BACTEC™ MGIT™ Automated Mycobacterial Detection System for comprehensive testing for TB, drug susceptibility and monitoring patients’ response to treatment. The BD MAX™ MDR-TB Assay complements this technology enabling clinicians to rapidly test for TB and multidrug resistance as a first-line test and then use the BD BACTEC™ MGIT™ System for broader drug susceptibility testing and patient monitoring. Learn More about TB Guardianship Program TB Guardianship Program Session 2 (bd.com).

New York Cancer & Blood Specialists Opens State-of-the-Art Cancer Center in Port Jefferson Station

Port Jefferson Station, NY, July 16, 2024 — New York Cancer & Blood Specialists (NYCBS), one of the Nation’s leading oncology practices, is proud to announce its new state-of-the-art comprehensive cancer center at 1500 Route 112, Building 1. The center is approximately 18,000 square feet and just across the parking lot from its previous location in Building 1.

“Our new facility represents a significant step forward in our mission to deliver world-class cancer care,” said Dr. Jeff Vacirca, Chief Executive Officer of NYCBS. “With this new space, we can see even more patients, ensuring everyone receives the timely and comprehensive care they need. This move allows us to provide integrated, patient-centered care in a modern and comfortable setting, reflecting our dedication to improving patient outcomes and experiences.”

The new facility, equipped with cutting-edge technology and expanded services, is designed to enhance patient care and comfort. NYCBS’s experienced oncologists will continue to provide comprehensive cancer care using the latest advancements. The new facility increases capacity, with 33 infusion chairs and 26 exam rooms, ensuring reduced wait times for timely and efficient treatment.

The advanced radiology department offers precise diagnostic imaging, featuring a 64-slice Evo CT scanner and ultrasound capabilities. A unique and significant feature of the new facility is the dedicated wellness suite, established through a partnership with Mondays at Racine. This suite provides free services to patients, such as oncology massage, skincare, and beauty treatments, to support their overall well-being. NYCBS remains dedicated to patients and their families, striving to make every visit as positive and supportive as possible.